Smoking Rates Hit Historic Low in US amid Pandemic

Mar.23.2022
Smoking Rates Hit Historic Low in US amid Pandemic
Smoking rates hit an all-time low in the US during the first year of the pandemic, attributed to public health campaigns and lifestyle changes.

According to foreign media reports on March 17, 2022, New York - in the first year of the COVID-19 pandemic, an increasing number of Americans have been abusing alcohol or using illegal drugs, but apparently not smoking.

 

According to survey data released on Thursday by the U.S. Centers for Disease Control and Prevention, smoking rates in the United States have reached a historic low in 2020, with only 1 in 8 adults reporting current use. The CDC also reported a decrease in adult e-cigarette usage.

 

Officials from the Disease Prevention and Control Center attributed this decline to public health campaigns and policies. However, outside experts suggest that increased prices for tobacco products and changes in lifestyle due to epidemics may have also played a role.

 

People who are mainly social smokers no longer have this situation," said Megan Roberts, a researcher at Ohio State University who focuses on tobacco product use among young people and adolescents.

 

More importantly, parents who suddenly had to stay home full-time with their children may have already cut back on expenses. Roberts also added that some individuals may have quit smoking after reports came out suggesting that smokers are more likely to develop severe illnesses if infected with COVID-19.

 

According to a report from the Centers for Disease Control and Prevention, based on a survey of over 31,000 American adults, 19% of Americans used at least one tobacco product in 2020, which is lower than the approximately 21% reported in 2019.

 

The use of cigars, smokeless tobacco, and pipes remain unchanged. Currently, the usage rate of electronic cigarettes has decreased from 4.5% in the previous year to 3.7%.

 

Cigarettes are the most commonly used tobacco product, with 12.5% of adults using them, which is lower than the 14% average.

 

For a long time, public health officials have believed that smoking - a risk factor for lung cancer, heart disease and stroke - is the leading cause of preventable deaths in the United States.

 

In 1965, 42% of American adults were smokers.

 

For several decades, this ratio has been gradually declining for various reasons, including taxes and smoking bans in workplaces and restaurants. However, some experts argue that a significant portion of the recent decline is due to the recent increase in prices.

 

For example, British American Tobacco - a company that produces brands such as Camel, Lucky Strike, and Newport - increased their prices fourfold in 2020, resulting in a total increase of around 50 cents per pack.

 

Interestingly, the amount of cigarettes sold in the United States actually increased in 2020, according to a report from the Federal Trade Commission. This is the first such growth in twenty years.

 

While there may be fewer smokers, those who do smoke tend to smoke more heavily.

 

This is a viable hypothesis - that people have more opportunities to smoke because they are not working," said David Sweanor, the global tobacco policy expert at the University of Ottawa.

 

He said that the investigation by the Disease Prevention and Control Center may also underestimate the number of smokers, either because some interviewees are dishonest or because the investigation missed too many smokers.

 

Other surveys have indicated that alcohol and illegal drug use have increased for many people during the first year of the pandemic.

 

(Source: Associated Press)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
VAPORESSO introduced the PRIX MTL pod system in August 2026 in two versions, Filter and NFC. The Filter version allows users to switch between a conventional drip tip and a filter tip, while the NFC version links interchangeable panels to matching on-screen animations. PRIX features a 2,600mAh battery, a 5.5ml pod, a 0.87-inch TFT display and a maximum output of 40W, alongside Dual Mesh Impact Pods capable of operating at two resistance and power configurations. VAPORESSO's French website lists MSRP at $39.99 for the Filter version and $49.90 for the NFC version.
Market
Aug.24 by 2Firsts Perspectives
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives